These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 25493582)

  • 1. The first Slovak experience with second-line vinflunine in advanced urothelial carcinomas.
    Palacka P; Mego M; Obertova J; Chovanec M; Sycova-Mila Z; Mardiak J
    Klin Onkol; 2014; 27(6):429-33. PubMed ID: 25493582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial.
    García-Donas J; Font A; Pérez-Valderrama B; Virizuela JA; Climent MÁ; Hernando-Polo S; Arranz JÁ; Del Mar Llorente M; Lainez N; Villa-Guzmán JC; Mellado B; González Del Alba A; Castellano D; Gallardo E; Anido U; García Del Muro X; Domènech M; Puente J; Morales-Barrera R; Pérez-Gracia JL; Bellmunt J
    Lancet Oncol; 2017 May; 18(5):672-681a. PubMed ID: 28389316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01-2014).
    Passalacqua R; Lazzarelli S; Donini M; Montironi R; Tambaro R; De Giorgi U; Pignata S; Palumbo R; Ceresoli GL; Del Conte G; Tonini G; Morelli F; Nolè F; Panni S; Rondini E; Guida A; Zucali PA; Doni L; Iezzi E; Caminiti C
    BMC Cancer; 2017 Jul; 17(1):493. PubMed ID: 28724419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1).
    De Santis M; Wiechno PJ; Bellmunt J; Lucas C; Su WC; Albiges L; Lin CC; Senkus-Konefka E; Flechon A; Mourey L; Necchi A; Loidl WC; Retz MM; Vaissière N; Culine S
    Ann Oncol; 2016 Mar; 27(3):449-54. PubMed ID: 26673352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN).
    Bellmunt J; Kerst JM; Vázquez F; Morales-Barrera R; Grande E; Medina A; González Graguera MB; Rubio G; Anido U; Fernández Calvo O; González-Billalabeitia E; Van den Eertwegh AJM; Pujol E; Perez-Gracia JL; González Larriba JL; Collado R; Los M; Maciá S; De Wit R;
    Ann Oncol; 2017 Jul; 28(7):1517-1522. PubMed ID: 28419193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vinflunine/gemcitabine versus carboplatin/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: A randomised phase II trial (VINGEM).
    Holmsten K; Jensen NV; Mouritsen LS; Jonsson E; Mellnert C; Agerbæk M; Nilsson C; Moe M; Carus A; Öfverholm E; Lahdenperä O; Brandberg Y; Johansson H; Hellström M; Maase HV; Pappot H; Ullén A
    Eur J Cancer; 2020 Mar; 127():173-182. PubMed ID: 31648851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of Vinflunine in Patients with Advanced Urothelial Carcinoma Refractory to Platinum-based Chemotherapy: A Prospective Pilot Study.
    Abdel-Malek R; Shohdy KS; Abbas N; Ismail M; Hamada E; Abdel-Kader Y
    Curr Drug Saf; 2019; 14(1):31-36. PubMed ID: 30277164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice.
    Castellano D; Puente J; de Velasco G; Chirivella I; López-Criado P; Mohedano N; Fernández O; García-Carbonero I; González MB; Grande E
    BMC Cancer; 2014 Oct; 14():779. PubMed ID: 25342282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen.
    Culine S; Theodore C; De Santis M; Bui B; Demkow T; Lorenz J; Rolland F; Delgado FM; Longerey B; James N
    Br J Cancer; 2006 May; 94(10):1395-401. PubMed ID: 16622447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy.
    Ikeda M; Matsumoto K; Tabata K; Minamida S; Fujita T; Satoh T; Iwamura M; Baba S
    Jpn J Clin Oncol; 2011 Oct; 41(10):1214-20. PubMed ID: 21903707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653).
    Sadeghi S; Groshen SG; Tsao-Wei DD; Parikh R; Mortazavi A; Dorff TB; Kefauver C; Hoimes C; Doyle L; Quinn DI; Newman E; Lara PN
    J Clin Oncol; 2019 Oct; 37(29):2682-2688. PubMed ID: 31390274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vinflunine in Metastatic Urothelial Carcinoma of the Bladder in Progression after a Platinum-Containing Regimen.
    De Luca R; Profita G; Vella M; Cicero G
    Oncology; 2019; 97(6):341-347. PubMed ID: 31461721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature.
    Oing C; Rink M; Oechsle K; Seidel C; von Amsberg G; Bokemeyer C
    J Urol; 2016 Feb; 195(2):254-63. PubMed ID: 26410730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study.
    Ardavanis A; Tryfonopoulos D; Alexopoulos A; Kandylis C; Lainakis G; Rigatos G
    Br J Cancer; 2005 Feb; 92(4):645-50. PubMed ID: 15685232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors in second-line treatment of urothelial cancers with gemcitabine and paclitaxel (German Association of Urological Oncology trial AB20/99).
    Niegisch G; Fimmers R; Siener R; Park SI; Albers P;
    Eur Urol; 2011 Nov; 60(5):1087-96. PubMed ID: 21839579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Activity of Sorafenib in Addition to Vinflunine in Post-Platinum Metastatic Urothelial Carcinoma (Vinsor): Phase I Trial.
    Shah CH; Pappot H; Agerbæk M; Holmsten K; Jäderling F; Yachnin J; Grybäck P; von der Maase H; Ullén A
    Oncologist; 2019 Jun; 24(6):745-e213. PubMed ID: 30552156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vinflunine in the Treatment of Upper Tract Urothelial Carcinoma - Subgroup Analysis of an Observational Study.
    Heers H; DE Geeter P; Goebell PJ; Matz U; DE Schultz W; Edlich B; Retz M; Hegele A
    Anticancer Res; 2017 Nov; 37(11):6437-6442. PubMed ID: 29061830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VICTOR: Vinflunine in advanced metastatic transitional cell carcinoma of the urothelium: A retrospective analysis of the use of vinflunine in multi-centre real life setting as second line chemotherapy through Free of Charge Programme for patients in the UK and Ireland.
    Hussain SA; Ansari J; Huddart R; Power DG; Lyons J; Wylie J; Vilarino-Varlela M; Elander NO; McMenemin R; Pickering LM; Faust G; Chauhan S; Jackson RJ
    Int J Oncol; 2017 Mar; 50(3):768-772. PubMed ID: 28098864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous 3-weekly paclitaxel and metronomic oral cyclophosphamide in patients with advanced urothelial cancer previously treated with gemcitabine and platinum.
    Park JH; Lee JL
    Cancer Chemother Pharmacol; 2015 Feb; 75(2):247-54. PubMed ID: 25428517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [First line therapy for local advanced or metastatic urothelial cell carcinoma: randomized phase II study to investigate the combination of vinflunine with gemcitabine and vinflunine with carboplatin in patients unfit for cisplatin therapy with advanced or metastatic urothelial cell carcinoma (JASINT-1 - AB 38/11) of AUO].
    Rexer H
    Urologe A; 2011 Aug; 50(8):974-6. PubMed ID: 21779884
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.